Why Jounce Therapeutics Stock Is Moving Higher Today?
The Board of Directors of Jounce Therapeutics Inc (NASDAQ:JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100%…
Reported Late Tuesday March 14, Jounce Therapeutics Confirms Receipt Of Unsolicited Proposal From Concentra Biosciences To Acquire 100% Of The Co. For $1.80/Share Subject To Diligence And Availability Of At Least $130M Of Cash And Equivalents At Closin…
The Board of Directors (the "Board") of Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer
SMBC Nikko Downgrades Jounce Therapeutics to Neutral
SMBC Nikko analyst David Dai downgrades Jounce Therapeutics (NASDAQ:JNCE) from Outperform to Neutral.
Redx and Jounce Merged To Form Redx; Redx Shareholders Will Own 63% and Jounce Shareholders 37% of Share Capital
Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction. Redx is a
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 314.3% to $16.24 during Wednesday’s regular session. Trading volume for…
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Gilead Sciences Inc (NASDAQ:GILD) and Jounce Therapeutics Inc (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to…
Cal-Maine Foods, Kala Pharmaceuticals And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket
Gainers
Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday.
Jounce Therapeutics Presents INNATE Phase 1 And SELECT Clinical Trial Data At The European Society Of Medical Oncology Immuno-Oncology Annual Congress
- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) -
- Patient with advanced biliary tract cancer who failed multiple lines